Authors
Latest:
What Direction Should Marginal Zone Lymphoma Research Be Heading?Tara M. Graff, DO, MS, stated that combination therapy approaches may be the optimal route forward for advancing MZL care.
Latest:
Collaborative Care and Access Challenges in Managing R/R MM with GPRC5D BispecificOncology Clinical Pharmacist Specialist Amir Ali delves into potential challenges related to access and the use of this therapy, providing a comprehensive perspective on the complexities of incorporating GPRC5-targeting bispecifics into R/R MM patient management.
Latest:
Perioperative Telemonitoring Yields “Encouraging” Results in GI CancersPatient-reported symptoms following surgery appear to improve with the use of perioperative telemonitoring, says Kelly M. Mahuron, MD.
Latest:
Oncology Peer Review On-The-Go Podcast: Cervical Cancer Screenings/Survival in Those 65+ YearsJulianne Cooley, MS, spoke with CancerNetwork® about older patients with later stage cervical cancer who have lower survival rates compared with their younger counterparts.
Latest:
Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in ItalyA survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.
Latest:
Addressing Social Norms Influencing Receipt of Aggressive End-of-Life CareAccording to Megan Mullins, PhD, MPH, challenging cultural norms surrounding death and dying may reduce the receipt of low-value end-of-life cancer care.
Latest:
Future Perspectives in the Treatment and Management of Patients With EGFR-Mutated NSCLCMisako Nagasaka, MD, PhD, and Kristen Neumann, DNP, FNP-C, emphasize the importance of patient education, discussing how understanding the biological reasons behind treatments for EGFR-mutated non-small cell lung cancer and their side effects can lead to better outcomes, and highlighting the need for collaborative care and clear communication.
Latest:
Treatment Considerations for Bispecific Antibodies and Unmet Needs in MMThe expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.
Latest:
Future of R/R MM: Emerging AgentsIn this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.
Latest:
Patient-Centered Approaches in EGFR-Mutated NSCLCPanelists discuss how oral and subcutaneous therapies have improved the quality of life for patients with EGFR-mutated advanced non–small cell lung cancer (NSCLC), with Squires sharing patient benefits from newer administration routes, and Dr Scott highlighting promising developments in EGFR-mutated NSCLC treatments, while exploring the evolving role of patient empowerment, self-management, and the multidisciplinary care team in supporting patients through home-based care and active participation in their treatment journey.
Latest:
FDA Grants Interchangeability Designation to 2 Denosumab BiosimilarsThe denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.
Latest:
Exploring New Possibilities in Kidney Cancer Detection and TherapyExperts discuss findings related to liquid biopsy profiling, later-line immunotherapy, and CDK4/6 inhibitor efficacy presented at the 2024 KCRS meeting.
Latest:
3 Things You Should Know About the Multimodal Treatment of SCLCHere are 3 things you should know about the multimodal treatment of patients with SCLC.
Latest:
Constantine Si Lun Tam, MD, MBBS, FRACP, FRCPA, on Key Highlights of the Phase 3 ASPEN TrialThe trial evaluated zanubrutinib, a potent and selective BTK inhibitor, versus ibrutinib, a first generation BTK inhibitor, in patients with Waldenström macroglobulinemia.
Latest:
A Phase 2 Study of Docetaxel and Capecitabine in Advanced Squamous Cell Carcinoma of the Head and NeckThis study explores the efficacy and safety of combining docetaxel and capecitabine for treating recurrent or metastatic head and neck cancer.
Latest:
Identifying Indications for Neoadjuvant Therapy in CholangiocarcinomaThe recent Hot Topics section focuses on survival rates for patients with cholangiocarcinoma.
Latest:
Recent Advances in the Understanding of MCL BiologyElias Campo, MD, PhD, provides insight into biological subtyping and the tumor microenvironment relating to mantle cell lymphoma.
Latest:
Reducing Animal Proteins, Increasing Fiber May Benefit Patients With CancerHydration and a healthy, well-balanced diet may mitigate fatigue among patients undergoing treatment for cancer.
Latest:
Benmelstobart With/Without Anlotinib Is Effective Consolidation Therapy in NSCLCBenmelstobart-based regimens provide clinically meaningful PFS benefits as consolidation therapy for unresectable stage III non–small cell lung cancer.
Latest:
Elevating the Quality of Cancer Care via Cross-Department CollaborationExperts from Sibley Memorial Hospital discuss how multidisciplinary work has enhanced outcomes such as survival and resource use at their institution.
